Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Kyndryl Holdings Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.52 (market cap $8.47B), while Kyndryl Holdings Inc trades at $11.78 (market cap $2.57B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 3.3× Kyndryl Holdings Inc's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Kyndryl Holdings Inc for 36 Days on average.
| HNGE | KD | |
|---|---|---|
Market Cap | $8.47B | $2.57B |
Volume | 1,624,526 | 3,294,342 |
Sector | Health | Technology |
52-Week High | $105.14 | $28.92 |
52-Week Low | $31.17 | $10.59 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $8.09B | $5.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Kyndryl (KD) trades at $12.24, up 3.9% on the day, with a neutral technical signal and bearish moving averages. The company reported a return to profitability in 2025 with net income of $252 million, though revenue has declined from prior years. Recent news highlights a strategic focus on AI, including the launch of an innovation lab and an acquisition to bolster healthcare IT services. Positive cash flow generation and a low EV/EBITDA of 3.8 suggest underlying value, but consecutive earnings misses and a high P/E ratio of 31.9 present challenges.
The investment outlook is mixed. A consensus price target of $14.67 implies potential upside, supported by strong operational cash flow and debt reduction. However, risks include declining revenue, thin net margins, and a majority 'Hold' analyst rating. The stock's performance hinges on successful execution of its AI strategy and reversing the top-line contraction seen in recent years.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
